Siegel CA - Search Results

1

ACG Clinical Guideline: Ulcerative Colitis in Adults.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. Rubin DT, et al. Among authors: siegel ca. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152. Am J Gastroenterol. 2019. PMID: 30840605

2

Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity.

Awais D, Siegel CA, Higgins PD. Awais D, et al. Among authors: siegel ca. Gut. 2009 Nov;58(11):1498-503. doi: 10.1136/gut.2008.169714. Epub 2009 Aug 2. Gut. 2009. PMID: 19651634

3

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2010 Oct;16(10):1658-62. doi: 10.1002/ibd.21233. Inflamm Bowel Dis. 2010. PMID: 20186940 Free PMC article.

4

Foam preparations for the treatment of ulcerative colitis.

Loew BJ, Siegel CA. Loew BJ, et al. Among authors: siegel ca. Curr Drug Deliv. 2012 Jul;9(4):338-44. doi: 10.2174/156720112801323062. Curr Drug Deliv. 2012. PMID: 21235478 Review.

5

IBS patients' willingness to take risks with medications.

Lacy BE, Everhart KK, Weiser KT, DeLee R, Strobel S, Siegel C, Crowell MD. Lacy BE, et al. Am J Gastroenterol. 2012 Jun;107(6):804-9. doi: 10.1038/ajg.2011.485. Am J Gastroenterol. 2012. PMID: 22664841

6

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Dulai PS, et al. Among authors: siegel ca. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22. Clin Gastroenterol Hepatol. 2014. PMID: 24462626 Review.

7

Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease.

Bressler B, Siegel CA. Bressler B, et al. Among authors: siegel ca. Gastroenterology. 2014 Apr;146(4):884-7. doi: 10.1053/j.gastro.2014.02.018. Epub 2014 Feb 25. Gastroenterology. 2014. PMID: 24576727 No abstract available.

8

An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.

Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, Siegel CA, Lewis JD. Bewtra M, et al. Among authors: siegel ca. Inflamm Bowel Dis. 2014 Jun;20(6):1070-8. doi: 10.1097/MIB.0000000000000053. Inflamm Bowel Dis. 2014. PMID: 24810138 Free PMC article.

9

Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.

Dulai PS, Siegel CA, Peyrin-Biroulet L. Dulai PS, et al. Among authors: siegel ca. Gastroenterol Clin North Am. 2014 Sep;43(3):441-56. doi: 10.1016/j.gtc.2014.05.009. Epub 2014 Jun 16. Gastroenterol Clin North Am. 2014. PMID: 25110252 Review.

10

The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.

Dulai PS, Siegel CA. Dulai PS, et al. Among authors: siegel ca. Gastroenterol Clin North Am. 2014 Sep;43(3):525-41. doi: 10.1016/j.gtc.2014.05.010. Epub 2014 Jun 13. Gastroenterol Clin North Am. 2014. PMID: 25110257 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters